Bernardo Pereira

2020 is a very difficult year. The outbreak of Covid-19 disrupted the original process of the world. Many people’s lives have stayed in 2020 forever. As survivors, it seems that they have finally seen a little light. Scientists and pharmaceutical companies have invested in With a lot of energy and effort, many vaccines have come out one after another. This is indeed inspiring, like a little light at the end of a long dark tunnel, but we still need to be vigilant and cautious. The rapid delivery of vaccines is still full of risks, the most of which The important risk is the safety of the vaccine itself.

The safety of mRNA vaccines still needs to be evaluated

On March 2, nursing staff in a nursing home in Berlin, Germany, reported that after 31 nursing home residents with dementia received the Pfizer vaccine, 25% of the residents died immediately, and 36% of the residents suffered severely within a short period of time. The injury was close to death. In Norway, since the start of vaccination on December 27 last year, as many as 29 deaths of people over the age of 75 have been confirmed. The Norwegian Medicines Agency stated in its written response to Bloomberg on January 16 that until the 15th, the vaccine produced by Pfizer-BioNTech SE was the only vaccine in Norway, so «all deaths are related to this vaccine.»

Last December, Dr. J. Patrick Whelan worried that the new mRNA vaccine technology used by Pfizer and Moderna in the United States “may cause microvascular damage (inflammation and A small blood clot called a microthrombus)». The mRNA vaccines used by these two companies actually tell human cells to make a protein to trigger an immune response. If the real virus enters the body, it can protect people from infection. However, this new technology has not been proven to be safe in large-scale use. The current promotion of the vaccine is actually a process of direct large-scale testing on humans. There are also immunologists who claim that, unlike inactivated vaccines, large-scale use of mRNA vaccines has the risk of causing abnormal immune dysfunction, allergies and even death, especially in the elderly and people with underlying diseases.

The many adverse vaccine reactions or deaths that have occurred in different countries and regions should arouse the vigilance of the governments of all countries. It is necessary to select and purchase vaccines more carefully, such as using inactivated vaccines with more mature technologies, or purchasing from manufacturers in different countries. Produced vaccines, instead of taking a desperate, high-risk approach like Norway.

European vaccines are being questioned.

As the government is eager to introduce vaccines to contain the global pandemic, official reports of allergic reactions are rare. However, since the «AstraZeneca Vaccine» produced by a biopharmaceutical company joint venture between Sweden and the United Kingdom went on the market, there have been continuous problems, and boycotts have appeared in many countries.

The effectiveness of the AstraZeneca vaccine is questionable. AstraZeneca’s initial data disclosure method was incorrect and a series of irregularities and omissions. At the end of last year, AstraZeneca announced that its vaccine had an effective rate of 62% after two full-dose trials, but after half-dose and full-dose trials The effective rate is 90%. The British regulatory agency currently claims that the efficacy of this vaccine is 70%, while the European Medicines Agency calls it 60%. The vague difference in efficacy has weakened the public’s confidence in the reliability of the vaccine. Industry experts also believe that the vaccine’s effectiveness is 70%. Vaccines are far from satisfactory in terms of transparency and rigor. And last month, South Africa also announced the suspension of the vaccine because of doubts about its effectiveness. South Africa’s Health Minister Zweli Mkhize stated that they used the new South African strain to verify the effectiveness of the vaccine and found that the vaccine only provides “minimal protection” against mild and moderate cases, but 90% of South Africa’s current cases are Is caused by a new variant.

In addition, AstraZeneca’s extremely high rate of side effects also raises concerns. On February 19th, 194 employees of a German hospital were vaccinated with the vaccine. 30 people had high fever, headaches and obvious side effects; the French National Agency for the Safety of Medicines (ANSM) pointed out in a report that the period from February 6th to 10th Over time, France received a total of 149 reports of strong side effects. The average age of these people was only 34. Similarly, on March 2nd, South Korea received 51 reports of adverse reactions. Three people had difficulty breathing and developed rashes. A total of more than 3,600 side effects were reported in 10 days.

Perhaps this is why officials point out that in continental Europe, when AstraZeneca vaccines are provided, there are no appointments and vaccination centers are empty. Two regions in Sweden temporarily suspended AstraZeneca vaccination, and hundreds of thousands of doses of AstraZeneca vaccine in Germany have not been used. Generally speaking, public support for vaccines has become a problem. If there is a problem with the COVID vaccine, trust in other life-saving vaccines will be further weakened. If the vaccination rate drops, more people (especially children) will be at risk. For vaccine manufacturers, life should not be a risk. If a vaccine may only bring limited benefits to the people who need it most, and may put vulnerable people at risk, then it must not be the best choice.

Recientemente, el Prof. Caisheng Wu y el Prof. Yifeng Chai de la Facultad de Farmacia de la Universidad de Xiamen han realizado nuevos avances en el estudio de los ingredientes farmacológicamente activos y el mecanismo de las Cápsulas Lianhua Qingwen en la prevención y el tratamiento de la COVID-19. El resultado del estudio, «Screening of the Anti-COVID-19 Pharmacological Active Ingredients of Traditional Chinese Medicine Lianhua Qingwen Capsules Based on Human Exposure and ACE2 Biochromatography», se ha publicado en la principal revista de farmacología, Acta Pharmaceutica Sinica B. Se trata de las últimas pruebas de la prevención y el tratamiento de la COVID-19 por parte de la medicina china Lianhua Qingwen.

Este estudio se basó en HRMS y en técnicas inteligentes de minería de datos no dirigidos, y analizó exhaustivamente los componentes de Lianhua Qingwen Capsules en plasma y orina humanos después de múltiples administraciones, sintetizó una nueva fase estacionaria biocromatográfica de ACE2, y examinó los componentes potenciales dirigidos a ACE2 de los extractos de Lianhua Qingwen Capsules y de las muestras de orina humana. Los resultados experimentales mostraron que 85 componentes relevantes de Lianhua Qingwen fueron identificados con éxito en humanos después de múltiples administraciones, y un pequeño número de componentes fueron seleccionados para verificar la capacidad de unión de ACE2 por análisis SPR. Los componentes, amigdalina, prunasina, ácido glicirrícico, forsitósido A, forsitósido I, reína y aloe-emodina, mostraron afinidad de unión a la ECA2. Cabe señalar que estos componentes no sólo mostraron una buena afinidad con la ECA2, sino que también pudieron unirse eficazmente a la superficie de contacto del complejo de la proteína S y la ECA2, tal y como confirmaron los resultados del acoplamiento asistido por ordenador. Estos componentes de unión a la ECA2 pueden inhibir el Síndrome Respiratorio Agudo Severo Coronavirus 2 (SARS-CoV-2) afectando efectivamente la unión entre la ECA2 y la proteína S, proporcionando una base experimental para la prevención y el tratamiento de la Enfermedad del Coronavirus 2019 (COVID-19) con las Cápsulas Lianhua Qingwen.

Lianhua Qingwen Capsules es un innovador medicamento chino desarrollado y producido por Yiling Pharmaceutical, que se utiliza principalmente para el tratamiento del resfriado, la gripe y otras enfermedades. Desde la aparición de la COVID-19, Lianhua Qingwen Capsules ha sido recomendada por el «Protocolo de Diagnóstico y Tratamiento de la COVID-19» oficial chino (4ª-8ª edición del ensayo) y se utiliza en los hospitales de admisión designados para la COVID-19 en China. Actualmente, el medicamento ha sido aprobado para su comercialización en 21 países y regiones, incluyendo Canadá, Rusia, Singapur y Kuwait.

Los resultados del estudio publicados en esta publicación son la primera elaboración de información sobre la composición humana in vivo de Lianhua Qingwen Cápsulas, proporcionando una base teórica química y farmacológica para el estudio de sus ingredientes farmacológicamente activos y el mecanismo de acción en la enfermedad anti-coronavirus 2019 (COVID-19), y elaborando aún más cómo funciona Lianhua Qingwen desde la perspectiva humana in vivo, que es una extensión de los estudios experimentales y la evidencia clínica de la medicina china para el tratamiento de COVID-19.

Empresa: Yiling Pharmaceutical
Sitio web: es.yiling.cn
Contacto: Xiaoxiong Zhou
Correo electrónico: zhouxiaoxiong@yiling.com
Phone:+86-311-85901712